RxDoctor Payments Data

Caroline Troise, MD

Internal Medicine · Providence, RINPI 1972509636

Payments from drug & device makers

$991in general payments, 2019–2025

Across 54 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$248
  • Novo Nordisk$186
  • Pfizer$104
  • E.r. Squibb & Sons, L.L.C.$58
  • GSK$55
  • Sanofi-aventis U.S. LLC$47
  • plus $294 from 13 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$991 in reported general payments places this provider in the 80th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$63,466
Medicare patients
302
Services billed
1,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$204,742
OzempicSemaglutide91$109,057
JardianceEmpagliflozin60$87,704
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$55,051
TriumeqAbacavir/Dolutegravir/Lamivudi13$45,984
Tresiba Flextouch U-200Insulin Degludec32$45,046
XareltoRivaroxaban20$26,080
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$23,184
Tresiba Flextouch U-100Insulin Degludec23$16,202
TrulicityDulaglutide14$15,582
FarxigaDapagliflozin Propanediol24$13,923
Breo ElliptaFluticasone/Vilanterol14$13,147
MounjaroTirzepatide11$11,119
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$10,927
Atorvastatin Calcium951$9,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$204,742224 claims
Novo NordiskOzempic$186$109,05791 claims
Viiv Healthcare CompanyTriumeq$16$45,98413 claims
Johnson & JohnsonXarelto$30$26,08020 claims
AbbVieLinzess, Synthroid$248$13,53757 claims
GSKBreo Ellipta$55$13,14714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →